FrancophonIA/ELRC3.0 huggingface dataset:
English: Proteoglycanes Of Klebsiella Pneumoniae 1.125mg Sachet, Ribosomes Of Haemophilus Influenzae 5 Units Sachet, Ribosomes Of Streptococcus Pneumoniae 30 Units Sachet, Ribosomal Fractions Of Klebsiella Pneumoniae 35 Units Sachet, Ribosomes From Streptococcus Pyogenes Group A 30 Units Sachet
Estonian: Klebsiella Pneumoniae proteoglükaanid 1 125 mg kotike, Haemophilus Influenzae ribosoomid 5 ühikut kotike, Streptococcus Pneumoniae ribosoomid 30 ühikut kotike, Klebsiella Pneumoniae ribosoomiosakesed 35 ühikut kotike, Streptococcus Pyogenes grupi A ribosoomid 30 ühikut kotike
English: Haemophilus Influenzae 6 Giga Cells Tablet, Klebsiella Ozaenae 6 Giga Cells Tablet, Klebsiella Pneumoniae 6 GigaCells Tablet, Neisseria Catarrhalis 6 Giga Cells Tablet, Staphylococcus Aureus 6 Giga Cells Tablet, Streptococcus Pneumoniae 6 Giga Cells Tablet, Streptococcus Pyogenes 6 Giga Cells Tablet, Streptococcus Oralis 6GigaCells Tablet
Estonian: Haemophilus Influenzae 6 Giga rakku tablett, Klebsiella Ozaenae 6 Giga rakku tablett, Klebsiella Pneumoniae 6 Giga rakku tablett, Neisseria Catarrhalis 6 Giga rakku tablett, Staphylococcus Aureus 6 Giga rakku tablett, Streptococcus Pneumoniae 6 Giga rakku tablett, Streptococcus Pyogenes 6 Giga rakku tablett, Streptococcus Oralis 6 Giga rakku tablett
English: Lyophilized Bacterial Lysates 7mg Capsule
Estonian: Lüofiliseeritud bakteriaalsed lüsaadid 7 mg kapsel
English: Haemophilus Influenzae 6 Giga Cells Tablet, Klebsiella Ozaenae 6 Giga Cells Tablet, Klebsiella Pneumoniae 6 Giga Cells Tablet, Neisseria Catarrhalis 6 Giga Cells Tablet, Staphylococcus Aureus 6 Giga Cells Tablet, Streptococcus Pneumoniae 6 Giga Cells Tablet, Streptococcus Pyogenes 6 Giga Cells Tablet, Streptococcus Viridans 6 Giga Cells Tablet
Estonian: Haemophilus Influenzae 6 Giga rakku tablett, Klebsiella Ozaenae 6 Giga rakku tablett, Klebsiella Pneumoniae 6 Giga rakku tablett, Neisseria Catarrhalis 6 Giga rakku tablett, Staphylococcus Aureus 6 Giga rakku tablett, Streptococcus Pneumoniae 6 Giga rakku tablett, Streptococcus Pyogenes 6 Giga rakku tablett, Streptococcus Viridans 6 Giga rakku tablett
English: Broncho-Vaxom Lyophilized Bacterial Lysates 3.5mg Sachet
Estonian: Broncho-Vaxom Lüofiliseeritud bakteriaalsed lüsaadid 3,5 mg kotike
English: Broncho-Vaxom Lyophilized Bacterial Lysates 7mg Capsule
Estonian: Broncho-Vaxom Lüofiliseeritud bakteriaalsed lüsaadid 7 mg kapsel
English: Broncho Vaxom Lyophilized Bacterial Lysates 7mg Capsule
Estonian: Broncho Vaxom Lüofiliseeritud bakteriaalsed lüsaadid 7 mg kapsel
English: Lysatum Bacteriale Mixtum 3.5mg Sachet
Estonian: Lysatum Bacteriale Mixtum 3,5 mg kotike
English: Lyophilized Bacterial Lysates 3.5mg Capsule
Estonian: Lüofiliseeritud bakteriaalsed lüsaadid 3,5 mg kapsel
English: Film-Coated Tablet
Estonian: Õhukese polümeerikattega tablett
English: Membranes Fractions Of Klebsiella Pneumoniae 15 Units Tablet, Ribosomes Of Haemophilus Influenzae 0.5 Units Tablet, Ribosomes Of Streptococcus Pneumoniae 3 Units Tablet, Ribosomal Fractions Of Klebsiella Pneumoniae 3.5 Units Tablet, Ribosomes From Streptococcus Pyogenes Group A 3 Units Tablet
Estonian: Klebsiella Pneumoniae membraaniosakesed 15 ühikut tablett, Haemophilus Influenzae ribosoomid 0,5 ühikut tablett, Streptococcus Pneumoniae ribosoomid 3 ühikut tablett, Klebsiella Pneumoniae ribosoomiosakesed 3,5 ühikut tablett, Streptococcus Pyogenes grupi A ribosoomid 3 ühikut tablett
English: Standardized Lyophylisate Of Bacterial Lysates 7mg Capsule
Estonian: Bakteriaalsete lüsaatide standardiseeritud lüofilisaat 7 mg kapsel
English: Membranes Fractions Of Klebsiella Pneumoniae 15 Units, Ribosomes Of Haemophilus Influenzae 0.5 Units, Ribosomes Of Streptococcus Pneumoniae 3 Units, Ribosomal Fractions Of Klebsiella Pneumoniae 3.5 Units, Ribosomes From Streptococcus Pyogenes Group A 3 Units
Estonian: Klebsiella Pneumoniae membraaniosakesed 15 ühikut, Haemophilus Influenzae ribosoomid 0,5 ühikut, Streptococcus Pneumoniae ribosoomid 3 ühikut, Klebsiella Pneumoniae ribosoomiosakesed 3,5 ühikut, Streptococcus Pyogenes grupi A ribosoomid 3 ühikut
English: Granules In Sachet
Estonian: Graanulid kotikeses
English: Standardized Lyophylisate Of Bacterial Lysates 3.5mg Capsule
Estonian: Bakteriaalsete lüsaatide standardiseeritud lüofilisaat 3,5 mg kapsel
English: 3 inhalers (3 x 30 doses) (multipack)
Estonian: 3 inhalaatorit (3x30 annust) (multipakend)
English: Strength Pharmaceutical Form Route of Administration
Estonian: Ravimvorm Manustamistee
English: Immediate Packaging
Estonian: Vahetu sisepakend Pakendi suurus
English: Pack size
Estonian: Liidus
English: 18 June 2012
Estonian: 18. juuni 2012
English: The final opinion was converted into a Decision by the European Commission on 18 June 2012.
Estonian: Lõplik arvamus kinnitati Euroopa Komisjoni otsusena 18. juunil 2012.
English: The referral procedure started on 14 September 2011.
Estonian: Esildise menetlemine algas 14. septembril 2011.
English: Written explanations were provided by the marketing authorisation holder on 2 December 2011.
Estonian: Müügiloa hoidja esitas kirjalikud selgitused 2. detsembril 2011.
English: Febantel is a probenzimidazole.
Estonian: Febanteel on probensimidasool.
English: These veterinary medicinal products are intended for the treatment of various parasitic infections in dogs caused by nematodes and cestodes.
Estonian: Need veterinaarravimid on näidustatud nematoodidest ja tsestoodidest põhjustatud mitmesuguste parasiitinfektsioonide raviks koertel.
English: The list of product names concerned is given in Annex I. The scientific conclusions are provided in Annex II, together with the amended summary of product characteristics, package leaflet and labelling in the Annex III.
Estonian: Asjaomased raviminimetused on I lisas, teaduslikud järeldused II lisas ning muudetud ravimi omaduste kokkuvõte, märgitus ja pakendi infoleht III lisas.
English: International non-proprietary name (inn): Praziquantel, pyrantel and febantel
Estonian: Rahvusvaheline mittekaubanduslik nimetus (INN): pratsikvanteel, püranteel ja febanteel
English: Milaxyn Plus, Strantel Plus, Prazical Plus, Voxical Plus, Exitel Plus, Cazitel Plus and Prazitel Plus (and associated names) are veterinary medicinal products as tablets for dogs containing 50 mg praziquantel, 50 mg pyrantel (equivalent to 144 mg pyrantel embonate) and 150 mg of febantel.
Estonian: Milaxyn Plus, Strantel Plus, Prazical Plus, Voxical Plus, Exitel Plus, Cazitel Plus ja Prazitel Plus (ja seotud nimetused) on veterinaarravimid, tabletid koertele, mis sisaldavad 50 mg pratsikvanteeli, 50 mg püranteeli (ekvivalentne 144 mg embonaatpüranteeliga) ja 150 mg febanteeli.
English: Pyrantel embonate (pamoate) is a tetrahydropyrimidine derivative.
Estonian: Embonaatpüranteel (pamoaat) on tetrahüdropürimidiini derivatiiv.
English: Praziquantel is a partially hydrogenated pyrazinoisoquinoline derivative.
Estonian: Pratsikvanteel on püratsinoisokvinoliini osaliselt hüdrogeenitud derivaat.
English: Opinion following an Article 34
Estonian: kohasele esildisele järgnev arvamus
English: Due to the divergent national decisions taken by Member States regarding the indications and use in pups less than 9 weeks of age and dogs weighing less than 2.5 kg concerning the authorisations of Milaxyn Plus, Strantel Plus, Prazical Plus, Voxical Plus, Exitel Plus, Cazitel Plus, Prazitel Plus and associated names, on 22 July 2011 France referred the issue to the CVMP under Article 34(1) of Directive 2001/82/EC, in order to resolve the above mentioned divergences.
Estonian: Et liikmesriigid olid ravimite Milaxyn Plus, Strantel Plus, Prazical Plus, Voxical Plus, Exitel Plus, Cazitel Plus, Prazitel Plus ja seotud nimetuste näidustuste ja kasutamise kohta alla 9-nädalastel kutsikatel ja alla 2,5 kg kaaluvatel koertel vastu võtnud erisuguseid otsuseid, tegi Prantsusmaa 22. juulil 2011 veterinaarravimite komiteele direktiivi 2001/82/EÜ artikli 34 lõike 1 kohase esildise, et eemaldada nimetatud erisused.
English: Based on the evaluation of the currently available data, the CVMP considered that the overall benefitrisk profile for Milaxyn Plus, Strantel Plus, Prazical Plus, Voxical Plus and associated names (authorised via Mutual Recognition Procedure No IE/V/0272-0275/001/MR) remains positive subject to variation of the marketing authorisations in accordance with the recommended changes to the product information.
Estonian: Tuginedes olemasolevate andmete hindamisele, otsustas veterinaarravimite komitee, et ravimite Milaxyn Plus, Strantel Plus, Prazical Plus, Voxical Plus ja seotud nimetuste (heaks kiidetud vastastikuse tunnustamise menetluse nr IE/V/0272-0275/001/MR alusel) kasulikkuse ja riski suhe on positiivne, kui müügilubadesse tehakse parandused vastavalt soovitatud muudatustele ravimiteabes.
English: Strantel Plus, Prazical Plus, Voxical Plus, Exitel Plus, Cazitel Plus and Prazitel Plus and associated names
Estonian: Ravimite Milaxyn Plus, Strantel Plus, Prazical Plus, Voxical Plus, Exitel Plus, Cazitel Plus ja Prazitel Plus ja seotud nimetuste artikli 34
English: terms of the marketing authorisations for Milaxyn Plus, Strantel Plus, Prazical Plus and Voxical Plus (and associated names) (authorised via Mutual Recognition Procedure No IE/V/0272-0275/001/MR) and the maintenance of the marketing authorisations for Prazitel Plus, Exitel Plus and Cazitel Plus (and associated names) (authorised via Mutual Recognition Procedure No IE/V/0241-0243/001/MR).
Estonian: veterinaarkomitee 7. märtsil 2012 positiivse otsuse, soovitades muuta ravimite Milaxyn Plus, Strantel Plus, Prazical Plus ja Voxical Plus (ja seotud nimetuste) (heaks kiidetud vastastikuse tunnustamise menetluse nr IE/V/0272-0275/001/MR alusel) müügilubade tingimusi ja säilitada ravimite Prazitel Plus, Exitel Plus ja Cazitel Plus (ja seotud nimetuste) (heaks kiidetud vastastikuse tunnustamise menetluse nr IE/V/0241-0243/001/MR alusel) müügiload.
English: Opinion following an Article 34F F referral for Milaxyn Plus, Strantel Plus, Prazical Plus, Voxical Plus, Exitel Plus, Cazitel Plus and Prazitel Plus and associated names EMA/289985/2012
Estonian: Ravimite Milaxyn Plus, Strantel Plus, Prazical Plus, Voxical Plus, Exitel Plus, Cazitel Plus ja Prazitel Plus ja seotud nimetuste artikli 34F F kohasele esildisele järgnev arvamus EMA/480402/2012
English: educational and social measures.
Estonian: pedagoogilised ja sotsiaalseid meetmed.
English: • it is used in children and adolescents aged 6-17 years.
Estonian: • seda kasutatakse lastel ja noorukitel vanuses 6...17 aastat;
English: • It should be used as part of a treatment programme which typically includes psychological,
Estonian: • Seda tuleb kasutada osana raviprogrammist, kuhu tavaliselt kuuluvad ka psühholoogilised,
English: • it is not indicated in all children with ADHD.
Estonian: • see ei ole näidustatud kõikidele ATH-ga lastele;
English: A comprehensive treatment programme typically includes psychological, educational and social measures.
Estonian: Kompleksravi hulka kuuluvad tavaliselt psühholoogilised, pedagoogilised ja sotsiaalsed meetmeid.
English: 4.1 Therapeutic indications [The wording of this section should read as follows]
Estonian: 4.1 Näidustused [Selle lõigu tekst peab olema järgmine]
English: Abuse, misuse, and diversion
Estonian: Kuritarvitamine, väärkasutamine ja kõrvaletoimetamine
English: Dexamfetamine possesses a high potential to cause dependency and has been/is frequently abused.
Estonian: Deksamfetamiinil on suur potentsiaal sõltuvuse tekitamiseks ja seda on sageli kuritarvitatud ja kuritarvitatakse.
English: Diagnosis should be made according to DSM-5 criteria or the guidelines in ICD-10 and should be based on a comprehensive multidisciplinary evaluation of the patient.
Estonian: Diagnoos peab vastama DSM-IV kriteeriumidele või RHK-10 juhendile ning tuginema patsiendi kompleksetele põhjalikele uuringutele.
English: Note: These amendments are to be incorporated to the valid Summary of Product Characteristics, labelling and package leaflet which are the final versions achieved during the Coordination group procedure
Estonian: Need muudatused tuleb teha kehtivas ravimi omaduste kokkuvõttes, pakendi märgistuses ja pakendi infolehes, mis on koordinatsioonirühma protseduuri käigus saavutatud lõplikud versioonid
English: • it is used only after when another medicine called methylphenidate was not sufficiently effective.
Estonian: • seda kasutatakse ainult pärast seda, kui ravi teise ravimi, metüülfenidaadiga ei olnud piisavalt efektiivne.
English: Treatment should be under the supervision of a specialist in childhood and/or adolescent behavioural disorders.
Estonian: Ravi peab toimuma laste ja/või noorukite käitumishäirete spetsialisti järelevalve all.
English: Dexamfetamine is not indicated in all children with ADHD and the decision to use dexamfetamine must be based on a very thorough assessment of the severity and chronicity of the child's symptoms in relation to the child's age and potential for abuse, misuse or diversion.
Estonian: Deksamfetamiin ei ole näidustatud kõigile ATH-ga lastele ning otsus deksamfetamiini kasutada peab põhinema lapsel esinevate sümptomite raskusastme ja kestuse põhjalikul analüüsil, arvestades sealjuures lapse vanust ja võimalikku kuritarvitamise, väärkasutamise või kõrvaletoimetamise ohtu.
English: Dexamfetamine is indicated as part of a comprehensive treatment programme for attentiondeficit/hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17 years when response to previous methylphenidate treatment is considered clinically inadequate.
Estonian: Deksamfetamiin on näidustatud aktiivsus- ja tähelepanuhäire (ATH) kompleksravi ühe osana lastel ja noorukitel vanuses 6 kuni 17 aastat, kui ravivastust varasemale metüülfenidaatravile loetakse kliiniliselt ebapiisavaks.
English: [The following sentence should be added in its place] The risk is generally greater for short acting stimulants than for corresponding long-acting products (see section 4.1).
Estonian: Lühikese toimeajaga stimulaatorite puhul on see risk üldjuhul suurem kui vastavate pika toimeajaga ravimite puhul (vt lõik 4.1).
English: WHAT DEXAMED IS AND WHAT IT IS USED FOR
Estonian: 1. MIS RAVIM ON DEXAMED JA MILLEKS SEDA KASUTATAKSE
English: Dexamed is used to treat attention-deficit/hyperactivity disorder (ADHD).
Estonian: Dexamedi kasutatakse aktiivsus- ja tähelepanuhäire (ATH) raviks.
English: Amendments to the summary of product characteristics and package leaflet
Estonian: Ravimi omaduste kokkuvõtte ja pakendi infolehe muudatused
English: Package leaflet: Information for the patient Dexamed 5 mg tablets
Estonian: Dexamed 5 mg tabletid Deksamfetamiinsulfaat
English: [The below wording should be inserted at the top of the document]
Estonian: [Alltoodud tekst tuleb lisada dokumendi algusesse]
English: [The following wording should be added at the end of this section]
Estonian: [Selle lõigu lõppu tuleb lisada järgmine tekst]
English: This will allow quick identification of new safety information.
Estonian: Käesoleva ravimi suhtes kohaldatakse täiendavat järelevalvet mis võimaldab kiiresti tuvastada uut ohutusteavet.
English: 4.8 Undesirable effects
Estonian: 4.9 Kõrvaltoimed
English: [These bullet points should read as follows]
Estonian: [Nendes punktides peab olema järgmine tekst]
English: [The wording below should be deleted]
Estonian: [Järgmine tekst tuleb kustutada]
English: The marketing authorisation was renewed on 21 March 2007.
Estonian: Müügiluba pikendati 21. märtsil 2007.
English: This summary was last updated in 09-2007.
Estonian: Kokkuvõtte viimane uuendus: 09-2007.
English: The marketing authorisation holder is Glaxo Group Ltd.
Estonian: Müügiloa hoidja on Glaxo Group Ltd.
English: Treatment should be started as soon as possible after diagnosis and continued for up to eight days or until the patient is discharged from hospital.
Estonian: Ravi tuleb alustada pärast diagnoosi niipea kui võimalik ja jätkata kuni kaheksa päeva jooksul või kuni patsient kirjutatakse haiglast välja.
English: For patients having surgery, the first dose should be given six hours after the end of the operation.
Estonian: Kirurgiapatsientidele tuleb esimene annus anda kuus tundi pärast operatsiooni lõppu.
English: However, these results were insufficient to show whether Quixidar was more effective than unfractionated heparin or not.
Estonian: Nendest andmetest siiski ei piisa osutamiseks, kas Quixidar on efektiivsem kui fraktsioneerimata hepariin või mitte.
English: In all studies, the main measure of effectiveness was the overall rate of thrombotic events (problems caused by blood clots).
Estonian: Kõikides uuringutes oli peamiseks efektiivsuse näitajaks tromboosijuhtude (trombide põhjustatud probleemid) üldine esinemissagedus.
English: When this is blocked, no thrombin (another factor) can be produced, and no clot can be formed.
Estonian: Kui see on blokeeritud, siis ei teki organismis trombiini (samuti hüübimistegur) ja hüüvet ei moodustu.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Quixidar on 21 March 2002.
Estonian: Euroopa Komisjon väljastas 21. märtsil 2002 Quixidari müügiloa, mis kehtib kogu Euroopa Liidu territooriumil.
English: The Committee recommended that Quixidar be given marketing authorisation.
Estonian: Komitee soovitas anda Quixidarile müügiloa.
English: It can also be used in patients at high risk (because of their age or disease) when they have abdominal surgery, especially for cancer, or when they are forced to stay in bed because of an acute illness.
Estonian: Seda võib kasutada ka patsientidel, kellel on vanuse või haiguse tõttu suur tüsistuste tekke risk, kui neile tehakse kõhuõõneoperatsioone (eriti vähktõve korral) või kui nad on sunnitud olema ägeda haiguse tõttu voodiravil.
English: EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) QUIXIDAR EPAR summary for the public
Estonian: EUROOPA AVALIK HINDAMISARUANNE QUIXIDAR Kokkuvõte üldsusele
English: As with other antithrombotic medicines, the most common side effect of Quixidar is bleeding.
Estonian: Nagu teistegi tromboosivastaste ravimite korral, on Quixidari kõige sagedam kõrvalnäht verejooks.
English: Quixidar is an anticoagulant; it prevents the blood from coagulating (clotting).
Estonian: Quixidar on antikoagulant - see takistab vere hüübimist (koagulatsiooni).
English: The dose may be adjusted, depending on body weight.
Estonian: Annust võib korrigeerida vastavalt patsiendi kehakaalule.
English: The main measure of effectiveness was the proportion of patients who died or had an ‘ischaemic event' (restriction of blood supply to an organ, including the heart).
Estonian: Efektiivsuse peamine näitaja oli nende patsientide osakaal, kes surid või kellel esines isheemiajuhtumeid (elundi, sh südame verevarustuse vähenemine).
English: Quixidar contains the active substance fondaparinux sodium (1.5, 2.5, 5, 7.5 or 10 mg per syringe).
Estonian: Quixidar sisaldab toimeainena naatriumfondapariinuksit (1,5 mg, 2,5 mg, 5 mg, 7,5 mg või 10 mg süstla kohta).
English: • without ‘ST segment elevation' (an abnormal reading on the electrocardiogram or ECG) in patients who are not going to undergo urgent angioplasty (within two hours): angioplasty or
Estonian: • ST-segmendi elevatsiooni (elektrokardiogrammi ehk EKG teatud ebanormaalne näit) puudumise korral patsientidel, kellele ei kavatseta teha kiireloomulist angioplastiat (kahe tunni jooksul).
English: Treatment should be continued until the risk of VTE has been reduced, usually at least five to nine days after surgery.
Estonian: tavaliselt vähemalt viis kuni üheksa päeva pärast operatsiooni.
English: For patients who have kidney problems, Quixidar may not be suitable, or the lower 1.5-mg dose may be used.
Estonian: Neeruhäiretega patsientide ravimiseks võib Quixidar mitte sobida või neil võib kasutada vähimat annust, 1,5 mg.
English: Other information about Quixidar:
Estonian: Muu teave Quixidari kohta
English: Medicinal Product no longer authorised
Estonian: European Medicines Agency
English: In the study of myocardial infarction with ST segment elevation, Quixidar reduced the risk of death or another heart attack by 14% after 30 days, compared to standard care.
Estonian: ST-segmendi elevatsiooniga südamelihaseinfarkti korral vähendas Quixidar 30 päeva järel surmariski või järgmise südameinfarkti riski tavalise raviga võrreldes 14%.
English: • with ‘ST segment elevation' in patients who are receiving thrombolytic medicines (‘clot busters')
Estonian: • ST-segmendi elevatsiooni olemasolu korral patsientidel, kes saavad trombolüütikume (ravimid,
English: Why has Quixidar been approved?
Estonian: Miks Quixidar heaks kiideti?
English: Blood clotting can be a problem when blood flow is disturbed in any way.
Estonian: Trombid ehk soonesisesed verehüübed võivad tekitada probleeme, kui verevarustus on mingil viisil häiritud.
English: ‘percutaneous coronary intervention' (PCI) is an operation to unblock the heart's blood vessels,
Estonian: Angioplastia ehk perkutaanne koronaarne interventsioon (PCI) on operatsioon, millega vabastatakse südame veresooned;
English: What is the risk associated with Quixidar?
Estonian: Millised on Quixidariga kaasnevad riskid?
English: Quixidar has also been studied in two main studies of patients with unstable angina or myocardial infarction.
Estonian: Quixidari uuriti ka kahes põhiuuringus patsientidel, kellel oli ebastabiilne rinnaangiin või südamelihase infarkt.
English: For the full list of all side effects reported with Quixidar, see the Package Leaflet.
Estonian: Quixidari kohta teatatud kõrvalnähtude täieliku loetelu leiate pakendi infolehelt.
English: or who are not about to receive any other treatment to restore blood flow to the heart.
Estonian: mis lahustavad trombe) või kellele ei kavatseta teha muid südame verevarustuse taastamise protseduure.
English: Quixidar is not recommended in patients who are about to undergo certain types of PCI.
Estonian: Quixidari ei soovitata kasutada patsientidel, kellele on kavas teha teatud liiki perkutaanset koronaarset interventsiooni.
English: The full EPAR for Quixidar can be found here.
Estonian: Quixidari Euroopa avaliku hindamisaruande täisteksti leiate siit.
English: It was also compared with placebo (a dummy treatment) when looking at patients with an acute illness (839 patients) and patients treated for an additional 24 days following hip fracture surgery (656 patients).
Estonian: Ravimit võrreldi ka platseeboga (näiva ravimiga), jälgides ägeda haigusega patsiente (839 patsienti) ja patsiente pärast puusamurru operatsiooni (656 patsienti).
English: In the treatment of DVT or PE, the recommended dose is 7.5 mg once a day by subcutaneous injection, usually for seven days.
Estonian: Süvaveenitromboosi või kopsuemboolia korral on soovitatav annus 7,5 mg üks kord päevas, manustatuna subkutaanse süstina, tavaliselt seitse päeva.
English: In the prevention of VTEs, the recommended dose of Quixidar is 2.5 mg once a day by subcutaneous injection (under the skin).
Estonian: Trombemboolia juhtude ennetamiseks on Quixidari soovitatav annus 2,5 mg üks kord päevas, manustatuna subkutaanse süstina (naha alla).
English: The effectiveness of Quixidar has been studied for the prevention of and in the treatment of VTE.
Estonian: Quixidari efektiivsust uuriti venoosse trombemboolia ennetuses ja ravis.
English: In the prevention studies, Quixidar was compared with other anticoagulants: enoxaparin (in hip or knee surgery; over 8,000 patients) or dalteparin (in abdominal surgery; 2,927 patients).
Estonian: Ennetusuuringutes võrreldi Quixidari teiste antikoagulantidega: enoksapariiniga (puusa- või põlveoperatsioonid; üle 8000 patsiendi) või daltepariiniga (kõhuõõneoperatsioonid; 2927 patsienti).
English: The 2.5 mg strength is also used to treat patients with unstable angina (a type of chest pain that changes in severity) or who are having a myocardial infarction (heart attack):
Estonian: 2,5 mg tugevusega Quixidari kasutatakse ka nende patsientide ravimiseks, kellel on ebastabiilne rinnaangiin (muutliku tugevusega valud rinnus) või südamelihaseinfarkt (südameinfarkt):